•  
  •  
  •  
  •  

2026-02-07 18:31:22

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Fusion Finance Q3 FY26: Disbursements Surge 23% QoQ to ₹1,594 Cr, PAT Swings to ₹14 Cr Profit
  • Nifty Recovers 200 Points to End the Session Near Day high
  • Gateway Distriparks Q3 FY26: Revenue Soars 39% to ₹566 Cr, PAT Up 4% - Declares ₹2 Special Dividend on Debt-Free Milestone
  • Mamaearth Onboards Sreeleela as Hair Care Category Brand Ambassador; Unveils Valentine's Day Film for Rosemary Anti-Hair Fall Shampoo
  • Wanbury Limited Q3 FY26: PAT Explodes 1,194% YoY to ₹15.8 Cr, Revenue Up 22%

Keywords Selected:  Tablets

Stock Report

  • Alembic Pharmaceuticals gets USFDA nod for generic Parkinson's disease treatment tablets
  • Zydus receives tentative approval from USFDA for Dapagliflozin Tablets, 5 mg and 10 mg
  • NATCO receives Tentative Approval for Erdafitinib Tablets from USFDA
  • Senores Pharmaceuticals, Inc. announces the approval and launch of Deferiprone Tablets USP, 500 mg & 1000 mg
  • Lupin receives tentative approval from U.S. FDA for Siponimod Tablets
  • SMS Pharmaceutical's associate company, VKT Pharma, receives US FDA approval for its reformulated Ranitidine
  • Zydus receives final approval from USFDA for Verapamil Hydrochloride Extended-Release Tablets USP, 120 mg, 180 mg and 240 mg
  • Marksans Pharma Inc. receives USFDA approval for Loperamide Hydrochloride Tablets USP, 2 mg (OTC).
  • Biocon Pharma Ltd receives approval from USFDA for its ANDA
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Diltiazem Hydrochloride Tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg
  • Zydus receives tentative approval from USFDA for Olaparib Tablets, 100 mg and 150 mg
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Dasatinib Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg
  • NATCO announces launch of its Everolimus tablets, 1 mg, (generic of Zortress®)
  • Biocon Pharma Ltd in partnership with Carnegie Pharmaceuticals LLC receives USFDA tentative approval for Rifaximin Tablets
  • Zydus receives approval from Health Canada for Liothyronine tablets 5 mcg and 25 mcg
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Paroxetine Extended Release Tablets USP, 25 mg and 37.5 mg.
  • Relonchem Limited receives Marketing Authorization for its products
  • ZyVet® launches affordable Furosemide tablets to support long-term heart care trusted diuretic for dogs and cats now available in a generic form
  • NATCO launches Bosentan Tablets for Oral Suspension in the United States with 180-day exclusivity
  • Lupin launches Bosentan Tablets for Oral Suspension in the United States with 180-Day Exclusivity
  • Alembic Pharmaceuticals Limited receives USFDA Final Approval for Macitentan Tablets, 10mg
  • Zydus receives final approval from USFDA for Diltiazem Hydrochloride Tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg
  • Shilpa Medicare announces the approval of Nor Ursodeoxycholic Acid Tablets 500 mg for the treatment of Non‐Alcoholic Fatty Liver Disease in India
  • Zydus receives final approval from USFDA for Prucalopride Tablets, 1 mg and 2 mg

Latest Post

  • Fusion Finance Q3 FY26: Disbursements Surge 23% QoQ to ₹1,594 Cr, PAT Swings to ₹14 Cr Profit
  • Nifty Recovers 200 Points to End the Session Near Day high
  • Gateway Distriparks Q3 FY26: Revenue Soars 39% to ₹566 Cr, PAT Up 4% - Declares ₹2 Special Dividend on Debt-Free Milestone
  • Mamaearth Onboards Sreeleela as Hair Care Category Brand Ambassador; Unveils Valentine's Day Film for Rosemary Anti-Hair Fall Shampoo
  • Wanbury Limited Q3 FY26: PAT Explodes 1,194% YoY to ₹15.8 Cr, Revenue Up 22%


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025